You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

KANJINTI Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: KANJINTI
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for KANJINTI
Recent Clinical Trials for KANJINTI

Identify potential brand extensions & biosimilar entrants

SponsorPhase
NRG OncologyPhase 2
Academic and Community Cancer Research UnitedPhase 2
Seagen Inc.Phase 1/Phase 2

See all KANJINTI clinical trials

Pharmacology for KANJINTI
Mechanism of ActionHER2/Neu/cerbB2 Antagonists
Established Pharmacologic ClassHER2/neu Receptor Antagonist
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for KANJINTI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for KANJINTI Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for KANJINTI Derived from Patent Text Search

No patents found based on company disclosures

KANJINTI Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for the Biologic Drug: KANJINTI

Introduction

KANJINTI, a biosimilar of the biologic drug trastuzumab (Herceptin), has been a significant player in the biosimilar market since its introduction. This article delves into the market dynamics and financial trajectory of KANJINTI, highlighting its impact on the healthcare industry and its financial performance.

What is KANJINTI?

KANJINTI (trastuzumab-anns) is a biosimilar developed by Amgen, designed to treat conditions such as breast cancer. It is highly similar to and functionally identical to the reference biologic, Herceptin, but offers a more cost-effective alternative[3].

Market Entry and Impact

KANJINTI was one of the first biosimilars to enter the trastuzumab market. Its entry marked a significant shift in market dynamics, as it immediately began to erode the market share of the originator, Herceptin. Data show that Herceptin started losing market share as soon as KANJINTI entered the market, and this trend continued with the subsequent entry of other biosimilars like Ogivri, Trazimera, Herzuma, and Ontruzant[4].

Market Share and Competition

KANJINTI maintained a strong first-mover advantage, securing a significant market share in most states. By December 2020, KANJINTI held approximately 39.6% of the market share, while the reference product, Herceptin, retained only about 45.3%. However, there was considerable variation in market share by state, with KANJINTI dominating in many regions but facing strong competition from other biosimilars in others[1].

State-by-State Variation

The market share of KANJINTI varied significantly across different states. For instance, it had a 100% market share in Washington, D.C., and Delaware, but in Alaska, Ogivri dominated with about 75% of the market share. This variability highlights the complex competitive landscape in the biosimilar market[1].

Pricing Dynamics

One of the key benefits of biosimilars is their ability to drive down prices. KANJINTI and other biosimilars entered the market with prices lower than the reference product. Over time, the average sales price (ASP) of all products, including the reference biologic, declined. By the second quarter of 2022, the ASPs of biosimilars ranged from 28% to 58% of the ASP of the reference product prior to biosimilar competition[1].

Price Competition

KANJINTI consistently had one of the lowest ASPs during the study period, although Ogivri briefly had a lower ASP in two quarters. This competitive pricing environment ensured that patients had access to more affordable treatment options[1].

Financial Performance

Revenue and Sales

KANJINTI's sales performance has been significant, although it has faced challenges in recent years. In the fourth quarter of 2022, KANJINTI sales decreased by 55% year-over-year, primarily due to lower net selling prices and unfavorable market conditions[5].

Amgen's Financial Reports

Amgen's financial reports reflect the broader trends in the biosimilar market. For instance, in the first quarter of 2024, Amgen's total revenues increased by 22%, driven by volume growth, but the company also reported higher operating expenses and a GAAP loss per share due to various factors, including the impact of the Horizon acquisition[2].

Regulatory Environment

The regulatory framework has been crucial in supporting the growth of the biosimilar market. Supportive policies in regions like Europe have encouraged the development and adoption of biosimilars, contributing to their increasing market presence[3].

Patient Access and Healthcare Costs

Biosimilars like KANJINTI have significantly improved patient access to critical treatments by offering cost-effective alternatives. This is particularly important given the escalating healthcare costs and the increasing incidence of chronic diseases. By providing lower-cost options, biosimilars help alleviate the financial strain on healthcare systems[3].

Prescribing Patterns

Research has shown that prescribing patterns for trastuzumab and its biosimilars vary between hospital-based and office-based physicians. Hospital-based physicians tend to prescribe either the biologic or a biosimilar exclusively, while office-based physicians prescribe more evenly across the different drug options[4].

Future Outlook

The biosimilar market, including KANJINTI, is expected to continue growing robustly. The global biosimilar market is projected to grow at a CAGR of 17.02% from 2024 to 2030, reaching nearly USD 74.70 billion by 2030. This growth is driven by factors such as patent expirations of biologic drugs, escalating healthcare costs, and the need for more accessible treatments[3].

Key Takeaways

  • Market Entry and Impact: KANJINTI's entry into the market significantly eroded the market share of the originator, Herceptin.
  • Market Share and Competition: KANJINTI maintained a strong first-mover advantage but faced competition from other biosimilars.
  • Pricing Dynamics: Biosimilars, including KANJINTI, have driven down prices, making treatments more affordable.
  • Financial Performance: KANJINTI's sales have been impacted by lower net selling prices and market conditions.
  • Regulatory Environment: Supportive regulatory frameworks have encouraged the growth of the biosimilar market.
  • Patient Access and Healthcare Costs: Biosimilars have improved patient access to treatments and helped reduce healthcare costs.

FAQs

What is KANJINTI?

KANJINTI (trastuzumab-anns) is a biosimilar of the biologic drug trastuzumab (Herceptin), used to treat conditions such as breast cancer.

How has KANJINTI impacted the market?

KANJINTI's entry into the market led to a significant reduction in the market share of the originator, Herceptin, and drove down prices, making treatments more affordable.

What is the current market share of KANJINTI?

By December 2020, KANJINTI held approximately 39.6% of the market share, although this varied significantly by state.

How has the pricing of KANJINTI evolved?

KANJINTI and other biosimilars entered the market with lower prices than the reference product, and their ASPs continued to decline over time.

What are the future prospects for the biosimilar market?

The global biosimilar market, including KANJINTI, is expected to grow at a CAGR of 17.02% from 2024 to 2030, driven by factors such as patent expirations and escalating healthcare costs.

How do prescribing patterns vary for KANJINTI and other biosimilars?

Hospital-based physicians tend to prescribe either the biologic or a biosimilar exclusively, while office-based physicians prescribe more evenly across different drug options.

Sources

  1. Trastuzumab Biosimilars Successfully Drove Down Prices - AJMC
  2. AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS - PR Newswire
  3. Biosimilar Market: Global Industry Analysis and Forecast (2024-2030) - Maximize Market Research
  4. Biosimilars Drug Market Isn't Broken After All, USC Schaeffer Study - USC Schaeffer
  5. AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS - Amgen

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.